AstraZeneca's Lynparza ups the ante at the PARP table with FDA's speedy breast cancer review

AstraZeneca's Lynparza currently bears approvals in ovarian cancer and ovarian cancer maintenance.

In June, AstraZeneca revealed that in a phase 3 trial, its Lynparza had pared down the risk of disease worsening or death in breast cancer patients by 42%. And that showing apparently impressed the FDA.

The agency Wednesday accepted the British drugmaker’s approval application and granted the medication its “priority review” tag. That means it’ll be a hasty trip for Lynparza—which AZ shares with Merck—through the regulatory review process. Regulators set a decision date in the first quarter of 2018, AZ said. 

RELATED: AstraZeneca's Lynparza, now in hot PARP battle, posts 42% survival win in breast cancer

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The "priority" nod comes on the back of study data showing that Lynparza—right now approved in ovarian cancer and ovarian cancer maintenance—shrank tumors in 60% of the HER2-negative breast cancer patients with BRCA1 or BRCA2 mutations. And importantly, it proved effective among patients with triple-negative breast cancer, a notoriously difficult-to-treat form of the disease.

If Lynparza can bring home an FDA nod, it’ll be the first PARP inhibitor to venture outside of the ovarian cancer arena. And that’ll open it up to sales its competitors—Clovis Oncology’s Rubraca and Tesaro’s Zejula—can’t currently touch.

RELATED: AstraZeneca's Lynparza, armed with new FDA nod, aims to regain share from Tesaro's Zejula

That’s not to say they aren’t working on it, though, making AZ’s potential head start all the more critical. Rubraca is in phase 2 studies for breast cancer and triple negative breast cancer, and Tesaro and Merck are testing a Zejula-Keytruda triple negative breast cancer combo that’s also in phase 2.

Meanwhile, AstraZeneca is hoping that August’s ovarian cancer maintenance approval can help Lynparza steal share back from Zejula, which has been steamrolling since its April launch. Both drugs now bear go-aheads in women without BRCA gene mutations.

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.